Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

26.02B

Market cap26.02B

Price-Earnings ratio

20.54

Price-Earnings ratio20.54

Dividend yield

—

Dividend yield—

Average volume

1.46M

Average volume1.46M

High today

$179.50

High today$179.50

Low today

$176.44

Low today$176.44

Open price

$178.68

Open price$178.68

Volume

160.33K

Volume160.33K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$114.66

52 Week low$114.66

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $177.31. The company's market cap stands at 26.02B, with a P/E ratio of 20.54.

As of 2026-04-16, Biogen(BIIB) stock has fluctuated between $176.44 and $179.50. The current price stands at $177.31, placing the stock +0.5% above today's low and -1.2% off the high.

The Biogen(BIIB)'s current trading volume is 160.33K, compared to an average daily volume of 1.46M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $114.66.

BIIB News

Nasdaq 5h

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

Key Points Biogen's quarterly updates haven't been impressive of late. It has made regulatory progress, but that won't be enough to boost top-line growth this...

Simply Wall St 6h

How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen Investors

On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleot...

TipRanks 3d

Biogen upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Biogen (BIIB) to Overweight from Neutral with a price target of $214, up from $177. The company’s acquisition of Apellis Pharmaceuticals...

Analyst ratings

49%

of 37 ratings

Buy

48.6%

Hold

45.9%

Sell

5.4%

More BIIB News

Simply Wall St 6d

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Biogen and Alloy Therapeutics have entered a new collaboration to develop multi target antisense oligonucleotide drugs using Alloy’s AntiClastic ASO platform....

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.